International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.

BACKGROUND Inflammatory breast cancer (IBC) represents the most aggressive presentation of breast cancer. Women diagnosed with IBC typically have a poorer prognosis compared with those diagnosed with non-IBC tumors. Recommendations and guidelines published to date on the diagnosis, management, and follow-up of women with breast cancer have focused primarily on non-IBC tumors. Establishing a minimum standard for clinical diagnosis and treatment of IBC is needed. METHODS Recognizing IBC to be a distinct entity, a group of international experts met in December 2008 at the First International Conference on Inflammatory Breast Cancer to develop guidelines for the management of IBC. RESULTS The panel of leading IBC experts formed a consensus on the minimum requirements to accurately diagnose IBC, supported by pathological confirmation. In addition, the panel emphasized a multimodality approach of systemic chemotherapy, surgery, and radiation therapy. CONCLUSIONS The goal of these guidelines, based on an expert consensus after careful review of published data, is to help the clinical diagnosis of this rare disease and to standardize management of IBC among treating physicians in both the academic and community settings.

[1]  A. Schneeweiss,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  S. Barsky,et al.  An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. , 2001, Cancer research.

[3]  A. Levine,et al.  Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. , 1993, Journal of the National Cancer Institute.

[4]  R. Pazdur,et al.  Cancer Management: A Multidisciplinary Approach , 2007 .

[5]  S. Romain,et al.  Inflammatory carcinomas of the breast: A clinical, pathological, or a clinical and pathological definition? , 1995, International journal of cancer.

[6]  T. Whelan,et al.  Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer , 2004, Canadian Medical Association Journal.

[7]  P. Bonnier,et al.  Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. , 1992, Anticancer research.

[8]  Andreas Makris,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Barsky,et al.  A novel human xenograft model of inflammatory breast cancer. , 1999, Cancer research.

[10]  A. Brufsky,et al.  Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Luc Y Dirix,et al.  Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification , 2004, Clinical Cancer Research.

[12]  C. Chow.  Imaging in inflammatory breast carcinoma. , 2005, Breast disease.

[13]  S. Teitelbaum,et al.  Inflammatory carcinoma of the breast. A Pathologic Definition , 1974, Cancer.

[14]  I. Günhan-Bilgen,et al.  Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases. , 2002, Radiology.

[15]  Thomas J. Smith,et al.  American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Zell,et al.  Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry , 2009, Breast Cancer Research.

[17]  Selin Carkaci,et al.  Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings , 2008, Breast Cancer Research and Treatment.

[18]  W. Woodward,et al.  Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. , 2008, International journal of radiation oncology, biology, physics.

[19]  S. Wells,et al.  Estrogen receptor status in inflammatory breast carcinoma , 1982, Journal of surgical oncology.

[20]  D. Mankoff,et al.  Evaluation of the Internal Mammary Lymph Nodes by FDG-PET in Locally Advanced Breast Cancer (LABC) , 2004, American journal of clinical oncology.

[21]  Theodore Y Kim,et al.  Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: a systematic review. , 2006, Clinical breast cancer.

[22]  大橋 広文.  Inflammatory carcinoma of the breastの1例 (乳癌(小特集)) , 1968 .

[23]  S. Devesa,et al.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. , 2005, Journal of the National Cancer Institute.

[24]  G. Fleming.  Locally Advanced, Locally Recurrent, and Metastatic Breast Cancer , 2003 .

[25]  J. Baselga,et al.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.

[26]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[27]  S. Merajver,et al.  RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. , 2000, Cancer research.

[28]  G. Hortobagyi,et al.  Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  S. Singletary,et al.  The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. , 2000, American journal of surgery.

[30]  J. Fricker.  San Antonio Breast Cancer Symposium. , 2009, The Lancet. Oncology.

[31]  O. Mawlawi,et al.  Retrospective Study of 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data , 2009, Journal of Nuclear Medicine.

[32]  C. Ewing,et al.  Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer , 2002, Annals of Surgical Oncology.

[33]  G. Hortobagyi,et al.  Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. , 2004, Clinical breast cancer.

[34]  G. Somlo,et al.  Esthetic reconstruction after mastectomy for inflammatory breast cancer: is it worthwhile? , 2000, Journal of the American College of Surgeons.

[35]  J. Daoud,et al.  [Breast cancer in Tunisia: clinical and epidemiological study]. , 1999, Bulletin du cancer.

[36]  S. Merajver,et al.  A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  M. Merino,et al.  The Role of 18F-FDG-PET in the Local/Regional Evaluation of Women with Breast Cancer , 2002, Breast Cancer Research and Treatment.

[38]  D. Schultz,et al.  Ten-year outcome after combined modality therapy for inflammatory breast cancer. , 2003, International journal of radiation oncology, biology, physics.

[39]  J. Baselga,et al.  Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. , 2009 .

[40]  G. Hortobagyi,et al.  Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center , 1997, Cancer Chemotherapy and Pharmacology.

[41]  C. D. HAAGENSEN,et al.  Diseases of the Breast , 1972 .

[42]  H. Schmoll,et al.  F.L. Greene, D.L. Page, I.D. Fleming et al. (eds). AJCC Cancer Staging Manual, 6th edition , 2003 .

[43]  Barbara L. Smith,et al.  Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  S. Hilsenbeck,et al.  Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. , 2003, Clinical breast cancer.

[45]  M. Dowsett,et al.  High incidence of HER-2 positivity in inflammatory breast cancer. , 2004, Breast.

[46]  S. Love,et al.  Recurrent Breast Cancer Following Immediate Reconstruction with Myocutaneous Flaps , 1994, Plastic and reconstructive surgery.

[47]  M. Phelps,et al.  18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  David A Mankoff,et al.  Evolving role of positron emission tomography in breast cancer imaging. , 2005, Seminars in nuclear medicine.

[49]  P. Levine,et al.  Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. , 1985, Journal of the National Cancer Institute.

[50]  C. Perez-Mesa,et al.  Inflammatory carcinoma of the breast , 1978, Cancer.

[51]  D. Slamon,et al.  Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  G. Hortobagyi,et al.  Prognostic significance of HER‐2 status in women with inflammatory breast cancer , 2008, Cancer.

[53]  Sofia D. Merajver,et al.  RhoC-GTPase is a Novel Tissue Biomarker Associated with Biologically Aggressive Carcinomas of the Breast , 2005, Breast Cancer Research and Treatment.

[54]  S. Steinberg,et al.  Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Gordon K. Lee,et al.  The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. , 2006, International journal of radiation oncology, biology, physics.

[56]  A. Amodio,et al.  [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results]. , 2007, La Clinica terapeutica.

[57]  P. Fumoleau,et al.  Inflammatory breast cancer outcome with epirubicin‐based induction and maintenance chemotherapy , 2006, Cancer.

[58]  G. Hortobagyi,et al.  The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[59]  B. Kaina,et al.  Rho GTPases are over‐expressed in human tumors , 1999, International journal of cancer.

[60]  T. Prochilo,et al.  Long-term results of combined-modality therapy for inflammatory breast carcinoma. , 2004, Clinical breast cancer.

[61]  A. Lammertsma,et al.  18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  S. Hilsenbeck,et al.  Molecular Heterogeneity of Inflammatory Breast Cancer: A Hyperproliferative Phenotype , 2006, Clinical Cancer Research.

[63]  T. Delozier,et al.  First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial) , 1999, British Journal of Cancer.

[64]  G. Hortobagyi,et al.  p53 Expression as a Prognostic Marker in Inflammatory Breast Cancer , 2004, Clinical Cancer Research.